New therapeutic opportunities for COVID-19 patients with Tocilizumab: Possible correlation of interleukin-6 receptor inhibitors with osteonecrosis of the jaws
Author links open overlay panelFrancescoBennardoCaterinaBuffoneAmerigoGiudice
Show more
https://doi.org/10.1016/j.oraloncology.2020.104659
To the Editor
A novel coronavirus (severe acute respiratory syndrome coronavirus 2, SARS-CoV-2; previously known as 2019-nCoV) emerged in Wuhan (Hubei, China) in December 2019 and spread rapidly across the planet. Several coronaviruses can cause light respiratory disease in humans but SARS-CoV-2 can cause a pneumonia, called corona virus disease-2019 (COVID-19) that might result in death due to massive alveolar damage and progressive respiratory failure [1]. Similarly to the “SARS-CoV” (emerged in 2003) and “MERS-CoV” (emerged in 2012), SARS-CoV-2 was probably hosted by bat and transmitted from other animals to humans [2]. The World Health Organization declared COVID-19 pandemic on March 12, 2020 [3].
